MLMarie L. Lindegaard

Marie L. Lindegaard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marie L. Lindegaard has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Alan T. Remaley

    Lipoprotein Metabolism Section, Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute, NIH, DHHS, Bethesda, MD, USA

    1 shared publication
  • Boris Vaisman

    Lipoprotein Metabolism Section, Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute, NIH, DHHS, Bethesda, MD, USA

    1 shared publication
  • Christopher A. Wassif

    Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA

    1 shared publication
  • Elizabeth V. Wasmuth

    Structural Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065

    1 shared publication
  • Forbes D. Porter

    Section on Molecular Dysmorphology, Program in Developmental Endocrinology and Genetics, Eunice Kennedy Schriver National Institute of Child Health and Human Development

    1 shared publication
  • Lars B. Nielsen

    Department of Clinical Biochemistry, Rigshospitalet

    1 shared publication

Latest Publications

  • Open Access

    Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith-Lemli-Opitz syndrome

    by Marie L. Lindegaard, Christopher A. Wassif, Boris Vaisman, Marcelo Amar, Elizabeth V. Wasmuth, Robert Shamburek, Lars B. Nielsen, Alan T. Remaley, Forbes D. Porter

    Patients with Smith–Lemli–Opitz syndrome (SLOS) are born with multiple congenital abnormalities. Postnatal cholesterol supplementation is provided; however, it cannot correct developmental malformations due to in utero cholesterol deficit. Increased transport of cholesterol from maternal to fetal circulation might attenuate congenital malformations. The cholesterol transporters Abca1, Abcg1, and Sr-b1 are present in placenta; however, their potential role in placental transport remains undetermined. In mice, expression analyses showed that Abca1 and Abcg1 transcripts increased 2–3-fold between embryonic days 13.5 and 18.5 in placental tissue; whereas, Sr-b1 expression decreased. To examine the functional role of Abca1, Abcg1 and Sr-b1 we measured the maternal–fetal transfer of 14C-cholesterol in corresponding mutant embryos. Disruption of either Abca1 or Sr-b1 decreased cholesterol transfer by ∼30%. In contrast, disruption of the Abcg1 had no effect. Treatment of pregnant C57Bl/6 female mice with TO901317, an LXR-agonist, increased both Abca1 expression and maternal–fetal cholesterol transfer to the fetus. In an SLOS mouse model (Dhcr7−/−), which is incapable of de novo synthesis of cholesterol, in utero treatment with TO901317 resulted in increased cholesterol content in Dhcr7−/− embryos. Our data support the hypothesis that Abca1, and possibly Sr-b1, contributes to transport maternal cholesterol to the developing fetus. Furthermore, we show, as a proof of principle, that modulating maternal–fetal cholesterol transport has potential for in utero therapy of SLOS.